Nasdaq · Healthcare
UroGen Pharma Ltd. (URGN)
As-reported financials and recent SEC filings for UroGen Pharma Ltd., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$109.8M
Net income
$-153.5M
Net margin
-139.8%
Diluted EPS
—
ROE
145.5%
P/E (TTM)
—
Market cap
—
Debt / equity
-1.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M |
| Operating income | $-124.9M | $-96.8M | $-65.5M | $-79.0M | $-92.3M |
| Net income | $-153.5M | $-126.9M | $-102.2M | $-109.8M | $-110.8M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →8-K2026-06-23
View on EDGAR →Largest Healthcare peers
Go deeper on URGN
Search UroGen Pharma Ltd.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.